Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

Table 3 Base case incremental cost utility results (lifetime horizon)

Strategy	Cost (S$)	Incremental cost (S$)	QALYs	Incremental QALYs	ICER (S$/QALY)
Calcium carbonate	152,988	0	5.81	0	0
Sevelamer	180,724	27,735.6	6.34	0.5359	51,756

All costs are in Singapore Dollars (S$). ICER incremental cost-effectiveness ratio. Although our study cohort all starts out not requiring dialysis, a large majority of them progress to end-stage renal disease and require dialysis by the end of the model simulation

ISSN: 1471-2369